Zosano Pharma

Zosano Pharma focuses on creating better products with its innovative drug delivery technology. Zosano's objective is to discover and develop therapeutic drug candidates that address large unmet medical needs or have a significant potential for commercialization. It was founded in 2006 and headquartered in Fremont, California.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES, Nov. 12, 2020 /PRNewswire/ -- The Law Offices of Frank R. Cruz reminds investors of the upcoming December 28, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Zosano Pharma Corporation ("Zosano"...

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Zosano Pharma Corporation (ZSAN)

New York, New York--(Newsfile Corp. - November 10, 2020) -  The Brualdi Law Firm, P.C. announces that a lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of Zosano Pharma Corporation ("Zosano" or the "Company") (NASDAQ: ZSAN) stock during the period between February 13, 2017 and September 30, 2020, inclusive (the "Class Period"), for violations of the federal securities laws.No class has yet been...

The Brualdi Law Firm, P.C. Announces Class Action Lawsuit against Zosano Pharma Corporation

BENSALEM, Pa., Nov. 10, 2020 /PRNewswire/ -- Law Offices of Howard G. Smith reminds investors of the upcoming December 28, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Zosano Pharma Corporation ("Zosano"...

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Zosano Pharma Corporation (ZSAN)

NEW YORK, Nov. 6, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Zosano Pharma Corporation ("Zosano" or the "Company") (NASDAQ: ZSAN) and certain of its officers. The class action, filed in United States District Court for the Northern...

Pomerantz Law Firm Announces the Filing of a Class Action against Zosano Pharma Corporation and Certain Officers - ZSAN

New York, New York--(Newsfile Corp. - November 4, 2020) - Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Zosano Pharma Corporation (NASDAQ: ZSAN) between February 13, 2017 and September 30, 2020, inclusive (the "Class Period"). The lawsuit seeks to recover damages for Zosano investors under the federal securities laws.To join the Zosano class action, go to http://www.rosenlegal.com/cases-register-1963.html or...

Rosen, Global Investor Counsel, Announces Filing of Securities Class Action Lawsuit Against Zosano Pharma Corporation; Encourages Investors with Losses in Excess of $100K to Contact the Firm - ZSAN

BENSALEM, Pa.--(BUSINESS WIRE)---- $ZSAN #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces Filing of a Securities Class Action on Behalf of Zosano Pharma Corporation (ZSAN) Investors

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Zosano Pharma Corporation (ZSAN) Investors

NEW YORK, Nov. 3, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Zosano Pharma Corporation ("Zosano" or the "Company") (NASDAQ: ZSAN) and certain of its officers, on behalf of...

ZSAN Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Zosano Pharma Corporation of Class Action and Encourages Shareholders to Contact the Firm

SAN DIEGO & FREMONT, Calif.--(BUSINESS WIRE)---- $ZSAN #ClassAction--Shareholder rights law firm Robbins LLP announces that a purchaser of Zosano Pharma Corporation (NASDAQ: ZSAN) filed a class action complaint against the Company and its officers and directors for alleged violations of the Securities & Exchange Act of 1934 between February 13, 2017 and September 30, 2020. Zosano Pharma is a clinical stage pharmaceutical company. If you suffered a loss due to Zosano Pharma's misconduct, click here. Zosano Pharma

Shareholder Alert: Robbins LLP Announces Zosano Pharma Corporation (ZSAN) is Being Sued for Misleading Shareholders

Investors will be keen on updates on Qtrypta when Zosano (ZSAN) reports Q3 results.

Is a Disappointment in Store for Zosano (ZSAN) Q3 Earnings?

LOS ANGELES--(BUSINESS WIRE)---- $ZSAN #ZSAN--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Zosano Pharma Corporation.

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Zosano Pharma Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)-- #Zosano--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of investors that purchased Zosano Pharma Corp. (NASDAQ: ZSAN) securities between February 13, 2017 and September 30, 2020 (the “Class Period”). Investors have until December 28, 2020 to apply to the Court to be appointed as lead plaintiff in the

ZOSANO ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Zosano Pharma Corp. and Encourages Investors to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $ZSAN #ZSAN--SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Zosano Pharma Corporation.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Zosano Pharma Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Zosano Pharma Corporation (NASDAQ: ZSAN) between February 13, 2017 and September 30, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Zosano investors under the federal securities laws. To join the Zosano class action, go to http://www.rosenlegal.com/cases-register-1963.html or call Phillip Kim, Es

ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Zosano Pharma Corporation – ZSAN

LOS ANGELES--(BUSINESS WIRE)---- $ZSAN #classaction--The Law Offices of Frank R. Cruz announces that it has filed a class action lawsuit in the United States District Court for the Northern District of California captioned Carr v. Zosano Pharma Corporation, et al., (Case No. 3:20-cv-07625) on behalf of persons and entities that purchased or otherwise acquired Zosano Pharma Corporation (“Zosano” or the “Company”)(NASDAQ: ZSAN) securities between February 13, 2017 and September 30, 2020, inclusive (the “Class Period”).

ZSAN CLASS ACTION NOTICE: The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against Zosano Pharma Corporation

LOS ANGELES--(BUSINESS WIRE)---- $ZSAN #CLASSACTION--ZSAN CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Zosano Pharma Corporation

ZSAN CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Zosano Pharma Corporation

LOS ANGELES--(BUSINESS WIRE)---- $ZSAN #classaction--The Law Offices of Frank R. Cruz announces an investigation of Zosano Pharma Corporation (“Zosano” or the “Company”) (NASDAQ: ZSAN) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On September 30, 2020, the Company revealed that it received “a discipline review letter (DRL) from the U.S. Food and Drug Administration (FDA) in connection with the Q

The Law Offices of Frank R. Cruz Announces Investigation of Zosano Pharma Corporation (ZSAN) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)---- $ZSAN #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Zosano Pharma Corporation (ZSAN) on Behalf of Investors

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Zosano Pharma Corporation (ZSAN) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)---- $ZSAN #CLASSACTION--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Zosano Pharma Corporation (ZSAN) on Behalf of Investors

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Zosano Pharma Corporation (ZSAN) on Behalf of Investors

-- FDA feedback consistent with FDA's preliminary communication in September-- --Company requesting meeting with FDA to discuss next steps required to resubmit the NDA-- FREMONT, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, announced today that it has received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) in connection with the Qtrypta™ (zolmitriptan transdermal microneedle system) 505(b)(2) New Drug Application (NDA).

Zosano Pharma Receives Complete Response Letter from FDA for Qtrypta™

FREMONT, Calif., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company today announced that it has received a discipline review letter (DRL) from the U.S. Food and Drug Administration (FDA) in connection with the Qtrypta™ (zolmitriptan transdermal microneedle system) 505(b)(2) New Drug Application (NDA). A DRL is used by the FDA to convey preliminary comments on deficiencies identified during the NDA review with respect to a particular review discipline.

Zosano Pharma Receives Preliminary FDA Communication on Qtrypta™ NDA

FREMONT, Calif., Sept.  09, 2020  (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo, will present a company overview at the Cantor Virtual Global Healthcare Conference on Tuesday, September 15, 2020 at 10:40 am ET.

Zosano Pharma to Present at the Cantor Virtual Global Healthcare Conference

FREMONT, Calif., Sept.  03, 2020  (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo, will present a company overview at the H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14, 2020 at 1:30 pm ET.

Zosano Pharma to Present at the H.C. Wainwright Annual Global Investment Conference

FREMONT, Calif., Aug.  31, 2020  (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be offered by Zosano. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Zosano Pharma Announces Proposed Public Offering of Common Stock

Sky Solar Hlds

DURECT

New Gold

Party City Holdco

SeaChange International

United Microelectronics

As we head further into August, a handful of penny stocks look like good opportunities. That said, here's seven penny stocks to buy.

7 Penny Stocks to Buy Right Now As Trends Catalyze Opportunity

Zosano Pharma (NASDAQ: ZSAN) shares are trading higher on Tuesday after the company announced an agreement to collaborate with Mitsubishi Tanabe Pharma Corp.

News for Zosano Pharma Stock (ZSAN)